CARLSMED INC

Company Overview

Carlsmed Inc. (Healthcare — Health Information Services; classified in medical equipment / surgical & medical instruments) develops the aprevo Technology Platform and a Digital Production System for spinal procedures; revenue was $12.1M in Q2 2025 (up 98.7% YoY) and $22.3M YTD (up 99.4% YoY), driven by higher procedure volumes and rising surgeon adoption (199 surgeon users through 6/30/25 vs. 116 a year earlier). Gross margins remain healthy (~73–74%) though Q2 compression was attributed to expedite production fees and higher material costs tied to meeting hospital timing needs. Management is investing heavily in commercial expansion, surgeon training, product/AI enhancements and a cervical commercialization (510(k) cleared Nov 2024; first cervical case July 2025), and the company completed an IPO on July 24, 2025 raising ~$93.5M net proceeds. Liquidity includes $33.5M cash and a $15.6M outstanding customer loan; key near-term risks are reimbursement changes, CMO capacity and regulatory/milestone delivery that can affect operations and financing.

Executive Compensation Practices

Given rapid commercial scaling and the recent IPO, compensation is likely shifting toward heavier equity-based pay (options/RSUs) to retain founders and commercial talent and to align incentives with long-term commercialization milestones. Short-term cash incentives and commissions will probably be tied to revenue, procedure volumes, surgeon adoption/penetration metrics, and gross-margin or cost-control targets as the company ramps sales and manufacturing. Material regulatory and reimbursement milestones (NTAP/X-code updates, MS-DRG outcomes, FDA clearances), and publication/clinical-data milestones (COMPASS Registry) are logical performance targets for both cash bonuses and performance-vesting equity because they directly affect hospital access and reimbursement. Because management flagged public-company readiness and potential additional financing, compensation programs may also include retention features and milestone-triggered equity vesting to limit dilution risk and preserve continuity through financing events. Finally, healthcare compliance concerns (physician relationships, anti-kickback exposure) will shape pay design to avoid perverse incentives tied to product utilization.

Insider Trading Considerations

The July 2025 IPO creates near-term structural constraints on insider trading (typical lock-up periods and heightened internal policies), but significant insider stock-based compensation and option grants can produce post-lockup selling or option exercises once restrictions lapse. Trading activity is likely to cluster around material commercial and regulatory events — e.g., quarterly revenue beats, major reimbursement approvals (NTAP/X-codes/MS-DRGs), publication of clinical data, or FDA/regulatory milestones for the cervical platform — so those dates are higher-probability windows for meaningful insider buys/sells. Because management repeatedly flags manufacturing/CMO capacity and milestone-linked loan terms, insiders may also transact around milestone/financing announcements; conversely, insider buys shortly after disappointing operational news can be a confidence signal. Standard regulatory controls apply (Section 16 reporting, blackout windows around earnings and material events), and insiders will often use pre-arranged 10b5‑1 plans to execute planned sales while avoiding the appearance of trading on non-public material information.